Tc 99m glucarate

Drug Profile

Tc 99m glucarate

Alternative Names: AMISCAN; Tc-99m-glucarate; Technetium glucarate; Technetium Tc 99m glucarate

Latest Information Update: 03 Aug 2015

Price : $50

At a glance

  • Originator Molecular Targeting Technologies
  • Developer DRAXIS Specialty Pharmaceuticals; Molecular Targeting Technologies
  • Class Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Sugar acids; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute coronary syndromes

Most Recent Events

  • 03 Aug 2015 No recent reports on development identified - Phase-II for Acute coronary syndromes (Diagnosis) in USA and Canada (IV)
  • 05 Jan 2005 DRAXIS Pharma has merged with DRAXIMAGE to form DRAXIS Specialty Pharmaceuticals
  • 25 Jul 2003 DRAXIMAGE and Bristol-Myers Squibb Imaging have extended and expanded their existing agreement in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top